Inactivation of dengue, chikungunya, and Ross River viruses in platelet concentrates after treatment with ultraviolet C light

Faddy, Helen M.; Fryk, Jesse J.; Prow, Natalie A.; Watterson, Daniel; Young, Paul R.; Hall, Roy A.; Tolksdorf, Frank; Sumian, Chryslain; Gravemann, Ute; Seltsam, Axel; Marks, Denese C.

doi:10.1111/trf.13519

Cited by 40 publications

(69 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been demonstrated that UVC treatment significantly reduces the infectivity of platelet products contaminated by disease‐causing bacteria, viruses, and protozoa. In addition, THERAFLEX UV‐Platelets inactivates contaminating donor WBCs while preserving platelet function and coagulation factors …”

mentioning

confidence: 99%

Bacterial inactivation of platelet concentrates with the THERAFLEX UV‐Platelets pathogen inactivation system

et al. 2018

Self Cite

View full text Add to dashboard Cite

BACKGROUND The THERAFLEX UV‐Platelets system (Maco Pharma) uses ultraviolet C (UVC) light for pathogen inactivation (PI) of platelet concentrates (PCs) without any additional photoactive compound. The aim of the study was to systematically investigate bacterial inactivation with this system under conditions of intended use. STUDY DESIGN AND METHODS The robustness of the system was evaluated by assessing its capacity to inactivate high concentrations of different bacterial species in accordance with World Health Organization guidelines. The optimal use of the PI system was explored in time‐to‐treatment experiments by testing its ability to sterilize PCs contaminated with low levels of bacteria on the day of manufacture (target concentration, 100 colony‐forming units/unit). The bacteria panel used for spiking experiments in this study included the World Health Organization International Repository Platelet Transfusion Relevant Reference Strains (n = 14), commercially available strains (n = 13), and in‐house clinical isolates (n = 2). RESULTS Mean log reduction factors after UVC treatment ranged from 3.1 to 7.5 and varied between different strains of the same species. All PCs (n = 12/species) spiked with up to 200 colony‐forming units/bag remained sterile until the end of storage when UVC treated 6 hours after spiking. UVC treatment 8 hours after spiking resulted in single breakthrough contaminations with the fast‐growing species Escherichia coli and Streptococcus pyogenes. CONCLUSION The UVC‐based THERAFLEX UV‐Platelets system efficiently inactivates transfusion‐relevant bacterial species in PCs. The comprehensive data from this study may provide a valuable basis for the optimal use of this UVC‐based PI system.

show abstract

mentioning

confidence: 99%

Bacterial inactivation of platelet concentrates with the THERAFLEX UV‐Platelets pathogen inactivation system

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…In the future, other approaches may be used, for example, PI, particularly in areas endemic for dengue. The Theraflex UV-Platelets System (MacoPharma) has been shown to inactivate DENV in spiked platelet units to the limit of detection of the assay used [19], as has the Theraflex-MB Plasma System (MacoPharma) for DENV spiked into plasma [20]. Similarly the Intercept Plasma Inactivation System (Cerus Corporation) demonstrated inactivation of DENV in spiked plasma to the limit of detection [21].…”

Section: Discussionmentioning

confidence: 99%

Mitigating the Risk of Transfusion-Transmitted Dengue in Australia

Rooks

Seed

Fryk

et al. 2016

Journal of Blood Transfusion

Self Cite

View full text Add to dashboard Cite

Dengue viruses (DENV 1–4) are a risk to transfusion safety, with several transfusion-transmitted (TT) cases reported globally. DENV 1–4 are endemic in over 100 countries, with seasonal outbreaks occurring in northeastern Australia. To mitigate TT-DENV risk in Australia, fresh blood components are not manufactured from donors returning from any area (domestic/overseas) with known dengue transmission. Alternatively, TT-DENV risk may be mitigated using an appropriate blood donor screening assay. We aimed to determine the rate of dengue infection in donors during dengue outbreaks in Australia. Plasma samples were collected from blood donors during local dengue outbreaks. All samples were tested for the presence of DENV RNA and selected samples were tested for DENV antigen (nonstructural protein 1, NS1) with two assays. No donors residing in high risk areas had detectable levels of DENV RNA or NS1 and no cases of DENV viremia were detected in blood donors residing in areas of Australia experiencing DENV outbreaks. Definitive conclusions could not be drawn from this study; however, the lack of detection of DENV RNA or antigen in donations suggests that the current risk of TT-DENV is low and maintaining the fresh component restriction for “at-risk” donors is appropriate.

show abstract

“…Andere umhüllte Viren wie Dengue Virus (DENV) 1-4, ChikungunyaVirus (CHIKV), Ross River Virus (RRV) und Zikavirus (ZIKV) wurden ebenfalls gut inaktiviert [128,131].…”

Section: Unerwünschte Effekte Der Pathogeninaktivierung Mit Mirasol®unclassified

Pathogen-Inaktivierungssysteme für Thrombozytenkonzentrate

2018

Bundesgesundheitsbl

View full text Add to dashboard Cite

Inactivation of dengue, chikungunya, and Ross River viruses in platelet concentrates after treatment with ultraviolet C light

Cited by 40 publications

References 40 publications

Bacterial inactivation of platelet concentrates with the THERAFLEX UV‐Platelets pathogen inactivation system

Bacterial inactivation of platelet concentrates with the THERAFLEX UV‐Platelets pathogen inactivation system

Mitigating the Risk of Transfusion-Transmitted Dengue in Australia

Pathogen-Inaktivierungssysteme für Thrombozytenkonzentrate

Contact Info

Product

Resources

About